Objective: To determine the risk of chronic lung disease (CLD) in small for gestational age (SGA) preterm infants in comparison to appropriately grown and large for gestational age (LGA) infants.

Methods: Observational study derived from a geographically defined population (Trent Health Region, United Kingdom). All preterm infants of or=90th centile). Both mortality and CLD rates (using both 28 days' and 36 weeks' postmenstrual age [PMA] definitions) were determined for these groups of infants.

Results: Four thousand fifty-one preterm infants
Conclusions: Fetal growth seems to influence mortality in general and morbidity, attributable to CLD, in particular in preterm infants. SGA preterm infants are at higher risk of death before 28 days' and 36 weeks' PMA and CLD by both definitions. LGA infants show reduced risk of CLD.

Download full-text PDF

Source
http://dx.doi.org/10.1542/peds.111.3.483DOI Listing

Publication Analysis

Top Keywords

chronic lung
8
lung disease
8
gestational age
8
preterm infants
8
disease prematurity
4
prematurity intrauterine
4
intrauterine growth
4
growth retardation
4
retardation population-based
4
population-based study
4

Similar Publications

Background: The impact of iron deficiency on COPD morbidity independent of anemia status is unknown. Understanding the association between iron deficiency, anemia status, and risk of hospitalization in COPD may inform an approach to these comorbidities.

Study Design And Methods: Adults ≥40 years from the Johns Hopkins COPD Precision Medicine Center of Excellence data repository with an outpatient iron profile and 1 year of subsequent follow-up time were included in the study.

View Article and Find Full Text PDF

Trajectory of the arterial-alveolar oxygen gradient in COPD for a decade.

PLoS One

January 2025

Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan.

Background: Chronic respiratory failure (CRF) is a critical complication in patients with chronic obstructive pulmonary disease (COPD) and is characterized by an increase in the arterial-alveolar oxygen gradient (A-aDO2). The long-term trajectory and prognostic significance remain unclear. This study aimed to assess the prognostic impact of A-aDO2 and elucidate its trajectory over ten years.

View Article and Find Full Text PDF

Nitric oxide synthase inhibitors reduce the formation of neutrophil extracellular traps and alleviate airway inflammation in the mice model of asthma.

Naunyn Schmiedebergs Arch Pharmacol

January 2025

Department of Pulmonary and Critical Care Medicine, Shanghai Fifth People's Hospital, Fudan University, Shanghai, 200240, China.

Asthma, a widespread chronic inflammatory disease can contribute to different degrees of lung function damage. The objective of this study is to explore the potential effects of nitric oxide synthase (NOS) inhibitors in asthma using mice model induced by ovalbumin (OVA). BALB/c mice were treated with OVA to establish an asthma model.

View Article and Find Full Text PDF

Radio-immunotherapy has antitumor activity but also causes toxicity, which limits its clinical application. JS-201 is a dual antibody targeting PD-1 and TGF-β signaling. We investigated the antitumour effect of JS-201 combined with radiotherapy and the effect on radiation-induced lung injury (RILI).

View Article and Find Full Text PDF

Background: Cardiopulmonary exercise testing (CPET) is usually considered the gold standard for assessing maximal oxygen consumption (V̇O), a health and performance marker in patients with chronic obstructive pulmonary disease (COPD). Despite the widespread application of CPET, the absolute and relative test-retest reliability of CPET-derived metrics remains unexamined.

Objective: To examine and compare test-retest reliability of CPET derived metrics in individuals with COPD and healthy matched controls.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!